A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC

Inclusion Criteria:

• Male and female patients age at least 18 years of age, or age of consent in theregion.

• Newly diagnosed Stage IIIB or IV non-small cell lung cancer (according to RevisedInternational System for Staging Lung Cancer criteria of 2010) or recurrent non-smallcell lung cancer (NSCLC).

• Histologically or cytologically confirmed diagnosis of predominately non-squamousNSCLC.

• Be eligible to receive study treatment of bevacizumab, paclitaxel, and carboplatinbased on local standard of care, for the treatment of advanced or metastaticnon-squamous NSCLC.

Exclusion Criteria:

• Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors andmixed adenosquamous carcinomas of predominantly squamous nature.

• Evidence of a tumor that compresses or invades major blood vessels or tumor cavitationthat is likely to bleed.

• Known sensitizing EGFR mutations (for example, deletion 19 or L858R) or EML4-ALKtranslocation positive mutations.

• Prior systemic therapy for NSCLC; prior neoadjuvant or adjuvant therapy is allowed ifsurgical resection for primary disease was performed.